This research demonstrates that targeting O-GlcNAcylated METTL3 reduces m6A modification and inhibits MDS and AML progression, indicating a new therapeutic avenue.
Key Points
Targeting O-GlcNAcylated METTL3 significantly impedes MDS and AML progression, demonstrating its crucial role in leukemogenesis.
Functional assays revealed that O-GlcNAcylation enhances METTL3 stability, correlating positively with MDS and AML cell survival.
The study utilized preclinical models to assess the impact of inhibiting O-GlcNAcylated METTL3 on the m6A-SRSF1-MCL-1 axis.
These findings highlight a novel therapeutic target that may provide new strategies for treating myeloid malignancies.